Syngene

Incorporated in the year 1994, Syngene International is one of India"s premier contract research and manufacturing organizations in providing customized service. Our services encompasses all across discovery chain: early stage discovery, process development, cGMP manufacturing and formulation development both in the small molecule and novel biologics area. Based in Bangalore, Karnataka, the Company is situated in a 90 acre Special Economic Zone with over 100000 sq. mt of built up facilities. The state-of-the-art research facilities have been qualified by various pharmaceutical majors & regulatory agencies and has received various certifications including ISO 9001: 2008, ISO 14001:2004, OHSAS 18001:2007, GLP and AAALAC.

Syngene International is one of India’s premier contract research and manufacturing organizations in providing customized service. Our services encompasses all across discovery chain: early stage discovery, process development, cGMP manufacturing and formulation development both in the small molecule and novel biologics area. Based in Bangalore, Karnataka, the Company is situated in a 90 acre Special Economic Zone with over 100000 sq. mt of built up facilities.

Syngene International is one of India’s premier contract research and manufacturing organizations in providing customized service. Our services encompasses all across discovery chain: early stage discovery, process development, cGMP manufacturing and formulation development both in the small molecule and novel biologics area. Based in Bangalore, Karnataka, the Company is situated in a 90 acre Special Economic Zone with over 100000 sq. mt of built up facilities.

Bristol-Myers Squibb Biocon R&D Center (BBRC) is a collaboration between Bristol-Myers Squibb and Syngene International, a subsidiary of the Indian biotechnology major, Biocon. This initiative is intended to help advance Bristol-Myers Squibb's work in discovery and early drug development. The center is expanding its capabilities to clinical biomarkers, toxicology and first-in-human studies. The aim is to develop internationally benchmarked research infrastructure and enlist outstanding scientific talent to help patients prevail against serious diseases. So come, research India with us.

Bristol-Myers Squibb Biocon R&D Center (BBRC) is a collaboration between Bristol-Myers Squibb and Syngene International, a subsidiary of the Indian biotechnology major, Biocon. This initiative is intended to help advance Bristol-Myers Squibb's work in discovery and early drug development. The center is expanding its capabilities to clinical biomarkers, toxicology and first-in-human studies. The aim is to develop internationally benchmarked research infrastructure and enlist outstanding scientific talent to help patients prevail against serious diseases. So come, research India with us.